May 30 2017
On Oct. 30, 2016, Canada signed the Comprehensive Economic and Trade Agreement with the European Union. Just one day later, Bill C-30: An Act to implement the Comprehensive Economic and Trade Agreement between Canada and the European Union and its Member States and to provide for certain other measures was introduced.
Among other changes, Bill C-30 introduces significant amendments to the existing regulatory scheme by which generic drugs are granted market authorization and new provisions for extending the term of certain pharmaceutical patents. The following provides a brief overview of the upcoming changes for pharmaceutical patents.
To read Andrew Montague and Ken Ma‘s full article, please visit the Canadian Lawyer InHouse Magazine’s website.
Back to blog overview
Tags: Bill C-30, Biotechnology & Pharmaceutical, CETA, Ken Ma